Protagonist Therapeutics ... (PTGX)
NASDAQ: PTGX
· Real-Time Price · USD
64.11
-0.59 (-0.91%)
At close: Sep 26, 2025, 11:04 AM
-0.91% (1D)
Bid | 46.9 |
Market Cap | 3.99B |
Revenue (ttm) | 203.63M |
Net Income (ttm) | 52.04M |
EPS (ttm) | 0.72 |
PE Ratio (ttm) | 89.05 |
Forward PE | -6595 |
Analyst | Buy |
Dividends | n/a |
Ask | 82.34 |
Volume | 219,746 |
Avg. Volume (20D) | 991,637.8 |
Open | 65.46 |
Previous Close | 64.70 |
Day's Range | 64.03 - 65.55 |
52-Week Range | 33.31 - 66.70 |
Beta | 2.22 |
Ex-Dividend Date | n/a |
About PTGX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol PTGX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for PTGX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsProtagonist Therapeutics Inc. is scheduled to release its earnings on
Nov 6, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
6 months ago
+45.89%
Protagonist Therapeutics shares are trading higher...
Unlock content with
Pro Subscription
6 months ago
+2.42%
Protagonist Therapeutics shares are trading higher after the company announced its Polycythemia Vera Phase 3 study with Takeda met all its key goals.

1 month ago · fool.com
Protagonist (PTGX) Q2 Revenue Falls 26%Protagonist (PTGX) Q2 Revenue Falls 26%

1 month ago · accessnewswire.com
Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateNDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque psoriasis (PsO) submitted to U.S. FDA in July ANTHEM Phase 2b trial data of ico...

3 months ago · accessnewswire.com
Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development CandidateWebcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below NEWARK, CA / ACCESS Newswire / June 26, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the...